摘要： Imagine an era where patients will be able to tell the doctor that they themselves have detected the target molecule (e.g., antigen, proteins, chemical molecule, etc.) related to a disease using a personalized diagnostic tools (e.g., glucose for diabetes, Salmonella typhi for typhoid, bilirubin for anemia). This may help the clinicians to quickly design the adequate therapeutic strategies for patients. A biosensor based diagnostic technology promises to do just that-quick onsite diagnosis. Biosensors in general are stand alone miniature portable devices that can detect range of analytes quickly with the help of transducers that converts the biological response into measurable analytical signals. It represents a rapidly expanding field currently and is expected to reach $22.68 billion market by 2020. Moving this proof-of-concept device for everyday analysis of biological or chemical samples has involved tremendous development in biosensors research [1]. Therefore, many such diagnostic devices are available in the global market for various medical purpose such as; malaria testing kit [(CareStart? Malaria HRP2/PLDH; Access Bio, United States) (Maleriscan? Malaria Pf/PAN; Bhat Bio-Tech (P) Ltd., India)], hCG based pregnancy testing kits [(Pregnosis?; Hoffmann-La Roche Ltd., Montreal), (Velocit?; Dr.Reddy’s India)], and portable glucometers [(CareStart? G6PD, Access Bio, United States)] etc. Although these miniaturized devices are extensively fabricated and possess good market potential, research to improvise the existing designs in terms of relativity, sensitivity, detection time, and point-of-care diagnosis are still underway [2].